Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 36.8% in November

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 549,400 shares, an increase of 36.8% from the November 15th total of 401,700 shares. Currently, 2.5% of the company’s stock are short sold. Based on an average trading volume of 72,700 shares, the days-to-cover ratio is presently 7.6 days.

Gyre Therapeutics Stock Performance

GYRE traded down $0.14 during trading on Friday, hitting $9.64. The stock had a trading volume of 139,162 shares, compared to its average volume of 121,390. The company’s 50-day moving average price is $13.07 and its 200 day moving average price is $12.59. Gyre Therapeutics has a twelve month low of $8.26 and a twelve month high of $30.40.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. FMR LLC bought a new position in Gyre Therapeutics in the third quarter worth about $47,000. Barclays PLC raised its holdings in shares of Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares during the period. State Street Corp grew its stake in Gyre Therapeutics by 8.8% during the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after acquiring an additional 8,412 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at about $123,000. Finally, Renaissance Technologies LLC bought a new stake in Gyre Therapeutics in the second quarter worth $166,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.